ApoA-I Mimetic administration, but not increased apoA-I-containing HDL, inhibits tumour growth in a mouse model of inherited breast cancer.

Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human...

Descripción completa

Detalles Bibliográficos
Autores: Cedó Giné, Lídia, García León, Annabel, Baila Rueda, Lucía, Santos, David, Grijalva, Victor, Martínez Cignoni, Melanie Raquel, Carbó, José M., Metso, Jari, López Vilaró, Laura, Zorzano Olarte, Antonio, Valledor Fernández, Annabel, Cenarro, Ana, Jauhiainen, Matti, Lerma, Enrique, Fogelman, Alan M., Reddy, Srinivasa T., Escolà Gil, Joan Carles, Blanco-Vaca, Francisco
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Universidad de Barcelona
Repositorio:Dipòsit Digital de la UB
OAI Identifier:oai:diposit.ub.edu:2445/118640
Acceso en línea:https://hdl.handle.net/2445/118640
Access Level:acceso abierto
Palabra clave:Càncer de mama
Hiperlipoproteïnes
Ratolins transgènics
Pèptids
Breast cancer
High density lipoproteins
Transgenic mice
Peptides
Descripción
Sumario:Low levels of high-density lipoprotein cholesterol (HDLc) have been associated with breast cancer risk, but several epidemiologic studies have reported contradictory results with regard to the relationship between apolipoprotein (apo) A-I and breast cancer. We aimed to determine the effects of human apoA-I overexpression and administration of specific apoA-I mimetic peptide (D-4F) on tumour progression by using mammary tumour virus-polyoma middle T-antigen transgenic (PyMT) mice as a model of inherited breast cancer. Expression of human apoA-I in the mice did not affect tumour onset and growth in PyMT transgenic mice, despite an increase in the HDLc level. In contrast, D-4F treatment significantly increased tumour latency and inhibited the development of tumours. The effects of D-4F on tumour development were independent of 27-hydroxycholesterol. However, D-4F treatment reduced the plasma oxidized low-density lipoprotein (oxLDL) levels in mice and prevented oxLDL-mediated proliferative response in human breast adenocarcinoma MCF-7 cells. In conclusion, our study shows that D-4F, but not apoA-I-containing HDL, hinders tumour growth in mice with inherited breast cancer in association with a higher protection against LDL oxidative modification

Similares en LA Referencia